Abstract:[Objective] To evaluate the value of application on BALB/c mice bearing liver cancer H22 imaging with hypoxia-avid agent ~(99)Tc~m HL91.[Methods] One mg HL91 was dissolved in 2 mL sterile sodium pertechnetate solution containing 1110 MBq(30mCi) ~(99)Tc~m.A stannous DTPA kit was reconstituted with 10 mL saline,an aliquot of 50 μL was removed and added to the vial containing HL91 and pertechnetate.After 10 minutes at room temperature,the radiochemical purity of the preparation of ~(99)Tc~m-HL91 was determined before use by paper and thin-layer chromatography,and exceeded 95%.There are 13 BALB/c mice bearing liver cancer HCa-F in the research.After anaesthesia,HL91(37 MBq) was injected intravenously.Three mice were underwent whole body planar static imaging after 2 h injection of ~(99)Tc~m-HL91,and five mice after 4 h,other five mice after 6h were also performed the same whole body planar imaging.Four regions of interest(ROI) were set on the tumor,head,abdomen and the thorax opposing to the thorax near tumor in the imaging.The radioactivity in the ROIs was measured.The tumor-to-normal tissue ratios of tumor to head,abdomen and thorax were calculated.[Results] All of the tumor were found ~(99)Tc~m-HL91 uptake.The uptake of HL91 in the tumor reached a peak at 4 h and then gradually decreased.After 6h postinjection of ~(99)Tc~m-HL91,the radioactivity of tumor was descended slightly.HL91 accumulated to highly levels in the hypoxic area than in other tissues except for abdomen.The tumor-to-normal tissue ratios of tumor to head,thorax and abdomen were 4.26±2.29,3.40±0.91,0.41±0.19,respectively.The ratio of T/NT at 4 h or 6 h is higher than that of 2 h,there were significant difference(P0.01).The T/NT continued increase until 6 h postinjection of ~(99)Tc~m-HL91.However,The radioactivity of abdomen was higher than tumor.[Conclusions] High uptake of ~(99)Tc~m-HL91 in the tumor of BALB/c mice bearing liver cancer H22(H-2),and the clearance rate is slower.High T/NT can be obtained after 4 h injection of ~(99)Tc~m-HL91.T/NT is a very important index in tumor hypoxic imaging.

Radioimmunoimaging of human hepatocellular carcinoma xenografts with 131I-anti-HBx monoclonal antibody

Tumor Radioimmunoimaging of Chimeric Antibody in Nude Mice with Hepatoma Xenograft.

Evaluation of radioimmunoimaging during radioimmunotherapy with monoclonal anti-human hepatocellular carcinoma antibodies

[Preparation of Monoclonal Antibody Directed Against Hepatitis B Virus X Protein and Detection of Reactive Antigen in Hepatocellular Carcinoma].

Evaluation of 131I-Anti-angiotensin II Type 1 Receptor Monoclonal Antibody As a Reporter for Hepatocellular Carcinoma

Non-invasive Imaging of Toll-like Receptor 5 Expression Using 131I-Labeled Mab in the Mice Bearing H22 Tumors

Radioimmunoimaging of 99mTc labelled humanized single-chain Fv dimers and immunonanoparticles for hepatocellular carcinoma in nude mice

Biodistribution and Localization of Iodine-131-Labeled Metuximab in Patients with Hepatocellular Carcinoma

Radioimmunotherapy for Hepatocellular Carcinoma (HCC) Using 131I-Anti HCC Isoferritin IgG: Preliminary Results of Experimental and Clinical Studies

Radioimmunoimaging of ~(153)Sm labeled anti-AFP monoclonal antibody in nude mice bearing human primary hepatic carcinoma

Preparation And Application Of Anti-Hbx/Anti-Cd3 Bispecific Monoclonal Antibody (Bsab) Retargeting Effector Cells For Lysis Of Human Hepatoma Xenografts In Nude Mice

Human Anti-(Murine Ig) Antibody Responses in Patients with Hepatocellular Carcinoma Receiving Intrahepatic Arterial 131 I-labeled Hepama-1 Mab. Preliminary Results and Discussion

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts

Treatment of Hepatocellular Carcinoma by Intratumoral Injection of 125I-AA98 Mab and Its Efficacy Assessments by Molecular Imaging.

99Mtc-Labeled HAb18 McAb Fab Fragment for Radioimmunoimaging in Nude Mice Bearing Human Hepatocellular Carcinoma.

Radioiodinated Anti-Hepatocellular Carcinoma (HCC) Ferritin Targeting Therapy, Tumor Imaging and Anti-Antibody Response in HCC Patients with Hepatic Arterial Infusion

Production of anti-HBx/CD3 BSAB secreting hybrid-hybridomas and application of the BSAB retargeting effector cells for lysis of human HCC xenografts in nude mice

Patient Dosimetry for 131I -Labeled Anti-HCC Mab (Hepama-1)

Evaluation of macrophage migration inhibitory factor as an imaging marker for hepatocellular carcinoma in murine models.

An Experimental Study on Mice Bearing Liver Cancer Imaging with ~(99)Tc~m-Hl91

[Biological Distribution of 131I-Hab18f(ab')2 in Patients with Hepatocellular Carcinoma].